High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy

Abstract Background Leptomeningeal metastasis in EGFR-mutant (EGFRm) non-small-cell lung cancer (NSCLC) is a severe complication particularly prevalent in patients who have previously been treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, an optimal treatment strategy for dealing wi...

Full description

Saved in:
Bibliographic Details
Main Authors: Shugui Wu, Zhengang Qiu, Huaqiu Shi, Wei Yu, Linfang Liu, Longqiu Wu, Wenjuan Zhong
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Cancer
Subjects:
Leptomeningeal metastasis
Intrathecal chemotherapy
Pemetrexed
Non-small-cell lung cancer
EGFR-tyrosine kinase inhibitors
Online Access:https://doi.org/10.1186/s12885-025-14337-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14337-z

Similar Items